The new immunoassay technology was unveiled at the recent American Association of Clinical Chemistry’s scientific meeting and clinical lab expo, held in Chicago.
Based on proprietary SPEAR technology, the NAB-Sure SARS-CoV-2 Assay is a powerful research tool in the fight against COVID-19 coronavirus disease. It serves a variety of applications, including COVID-19 serosurveillance, vaccine efficacy testing, and longitudinal antibody durability testing.
The immunoassay test kit is capable of ultrasensitive protein detection for small sample sizes, such as dried blood spot (DBS) samples from a finger prick, which can be collected in-home. The assay has high concordance with the accuracy of plaque-reduction neutralization testing (PRNT), without the safety concerns and long workflows of a cell-based test. NAB-Sure SARS-CoV-2 Assay offers a critical boost to COVID-19 vaccine developers, clinical laboratories, and healthcare researchers.
SPEAR technology aims to enhance testing for SARS-CoV-2 NAbs with ultrasensitive automated testing compatibility support for many sample types, including DBS, plasma, and serum, and excellent laboratory-to-laboratory consistency in measurement results even when comparing different sample types.
Meanwhile, Spear Bio’s co-founder and CTO, Feng Xuan, and Yu Wang, PhD, head of application development, were recognized as the 2022 AACC Division Award Winner for the Best Abstract in Metabolomics for their technical poster B-087: “A Novel Ultrasensitive High Throughput and Quantitative SARS CoV 2 Neutralizing Antibody Titer Measurement Assay in Dried Blood Spot Samples.”
Spear Bio’s validated SPEAR technology aims to provide a pathway to COVID-19 healthcare solutions for researchers facing tight constraints and with limited sample sizes, such as government agencies or research firms working with micro-sampling collection devices like DBS.